重症监护多学科团队中临床药师参与对患者结局的影响:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、EMBASE及既往相关系统研究参考文献,从4725篇潜在 eligible 文献中纳入14项报告死亡率、ICU住院时间及不良药物事件的随机对照试验和非随机研究。与无临床药师干预相比,重症监护药师作为多学科ICU团队一部分与死亡率降低显著相关(OR 0.78,95%CI 0.73-0.83,P<0.00001)。混合ICU住院时间平均差为-1.33天(95%CI -1.75至-0.90天,P<0.00001)。可预防和不可预防不良药物事件发生率降低亦与含药师干预的多学科团队诊疗显著相关(OR分别为0.26,95%CI 0.15-0.44,P<0.00001;OR 0.47,95%CI 0.28-0.77,P=0.003)。结论认为,将重症监护药师纳入多学科ICU团队改善了患者结局。
要点
- 与无临床药师干预相比,重症监护药师参与多学科ICU团队与死亡率降低显著相关(OR 0.78,95%CI 0.73-0.83,P<0.00001)。
- 混合ICU中,药师参与多学科团队与ICU住院时间缩短相关,平均差-1.33天(95%CI -1.75至-0.90天,P<0.00001)。
- 药师参与多学科团队与可预防不良药物事件减少显著相关(OR 0.26,95%CI 0.15-0.44,P<0.00001)。
- 药师参与多学科团队与不可预防不良药物事件减少亦显著相关(OR 0.47,95%CI 0.28-0.77,P=0.003)。
- 该系统评价与Meta分析共纳入14项报告临床结局的随机对照试验和非随机研究。
适用人群与场景
- 纳入报告死亡率、ICU住院时间及不良药物事件等临床结局、设有临床药师干预组与无干预组的随机对照试验和非随机研究。
研究设计与关键结果
- 系统评价与Meta分析,从4725篇潜在 eligible 文献中纳入14项随机对照试验和非随机研究。
- 与无临床药师干预相比,重症监护药师作为多学科ICU团队一部分与死亡率降低显著相关(OR 0.78,95%CI 0.73-0.83,P<0.00001)。
- 混合ICU住院时间平均差为-1.33天(95%CI -1.75至-0.90天,P<0.00001)。
- 可预防不良药物事件减少与含药师干预的多学科团队诊疗显著相关(OR 0.26,95%CI 0.15-0.44,P<0.00001)。
- 不可预防不良药物事件减少亦与含药师干预的多学科团队诊疗显著相关(OR 0.47,95%CI 0.28-0.77,P=0.003)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验和非随机研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,将重症监护药师纳入多学科ICU团队改善了患者结局,包括死亡率、混合ICU住院时间及可预防/不可预防不良药物事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The objective of this systematic review and meta-analysis was to assess the effects of including critical care pharmacists in multidisciplinary ICU teams on clinical outcomes including mortality, ICU length of stay, and adverse drug events.
DATA SOURCES: PubMed, EMBASE, and references from previous relevant systematic studies.
STUDY SELECTION: We included randomized controlled trials and nonrandomized studies that reported clinical outcomes such as mortality, ICU length of stay, and adverse drug events in groups with and without critical care pharmacist interventions.
DATA EXTRACTION: We extracted study details, patient characteristics, and clinical outcomes.
DATA SYNTHESIS: From the 4,725 articles identified as potentially eligible, 14 were included in the analysis. Intervention of critical care pharmacists as part of the multidisciplinary ICU team care was significantly associated with the reduced likelihood of mortality (odds ratio, 0.78; 95% CI, 0.73-0.83; p < 0.00001) compared with no intervention. The mean difference in ICU length of stay was -1.33 days (95% CI, -1.75 to -0.90 d; p < 0.00001) for mixed ICUs. The reduction of adverse drug event prevalence was also significantly associated with multidisciplinary team care involving pharmacist intervention (odds ratio for preventable and nonpreventable adverse drug events, 0.26; 95% CI, 0.15-0.44; p < 0.00001 and odds ratio, 0.47; 95% CI, 0.28-0.77; p = 0.003, respectively).
CONCLUSIONS: Including critical care pharmacists in the multidisciplinary ICU team improved patient outcomes including mortality, ICU length of stay in mixed ICUs, and preventable/nonpreventable adverse drug events.
参考来源
- Lee H, Ryu K, Sohn Y, et al. Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis. Crit Care Med. 2019. PMID: 31135496. doi:10.1097/CCM.0000000000003830
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。